Medtronic sidesteps whistleblower suit
This article was originally published in The Gray Sheet
Executive Summary
Gilligan v. Medtronic dismissed by U.S. Court of Appeals for the Sixth Circuit because the plaintiff's grounds for allegations were publicly disclosed already and thus exempt from the False Claims Act, Washington Legal Foundation reports April 13. WLF had filed a brief supporting Medtronic and urging dismissal on the grounds that the Supreme Court's 2001 Buckman decision precluded all fraud-on-FDA claims. Attorneys Louis Gilligan and Gregory Utter attempted to sue Medtronic on behalf of the U.S. government, citing malfunctions with two pacemaker leads that have been off the market for more than a decade...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.